Trials / Available
AvailableNCT04085653
Managed Access Programs for BYL719, Alpelisib
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this registration is to list Managed Access Programs (MAPs) related to BYL719, Alpelisib
Detailed description
CBYL719F12001M - Available - Managed Access Program (MAP) Cohort to provide access to Alpelisib (BYL719) for patients with PIK3CA-Related Overgrowth Spectrum (PROS) CBYL719C2001M - Available - Managed Access Program (MAP) Cohort to provide access to alpelisib (BYL719) for patients with HR-positive, HER2-negative advanced breast cancer with mutated phosphoinositide 3-kinase who progressed on or after AI treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | alpelisib | Patients receive alpelisib |
Timeline
- First posted
- 2019-09-11
- Last updated
- 2026-04-14
Source: ClinicalTrials.gov record NCT04085653. Inclusion in this directory is not an endorsement.